A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Inclusion Criteria:

• Participant must be 18 to 75 years of age inclusive.

• BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity.

• A stable, self-reported body weight for 3 months prior to screening.

• Male and female participants: Contraceptive use by males or females should beconsistent with local regulations regarding the methods of contraception for thoseparticipating in clinical studies.

• Female participants must have a negative serum pregnancy test at screening and anegative urine pregnancy test at baseline.

• Capable of giving signed informed consent.

Exclusion Criteria:

• History of any clinically important disease or disorder, which, in the opinion ofthe Investigator, may put the participant at risk.

• History or presence of GI, renal, hepatic disease.

• Previous or planned bariatric surgery or fitting of a weight loss device.

• Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma orPrader-Willi syndrome.

• History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucosecontrol.

• HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or randomglucose ≥ 200 mg/dL (11.1 mmol/L).

• Significant gastric and hepatobiliary disease.

• History of acute or chronic pancreatitis or pancreatic amylase or lipase > 2 × ULNat screening.

• History of psychosis or bipolar disorder.

• History of major depressive disorder within the 2 years prior to screening ordepression.

• Treatment with a GLP1 containing preparation, either as part of treatment or whileparticipating in another clinical study within the 3 months or 5 half-lives of thedrug prior to screening.

• Vulnerable populations